Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02900469 · ClinicalTrials.gov registry record · Early Phase 1

Presurgical Trial of Denosumab in Breast Cancer

A Early Phase 1 study, sponsored by NYU Langone Health.

Completed
Registry status
Early Phase 1
Development phase
44
Enrollment target

NCT02900469: Completed Early Phase 1 study, sponsored by NYU Langone Health.

NCT02900469 is a Early Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 44 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02900469, a Early Phase 1 study, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
Early Phase 1
Development phase
44 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether one dose of denosumab can lead to changes in the tumor, which may decrease the ability of tumor to spread.

Primary Outcome

Immunohistochemical analyses (IHC) of RANK and RANKL protein expression will be performed by Clarient Diagnostics Services Inc., Aliso Viejo, CA using prototype assays developed and optimized by Dako on their automated staining platform

Interventions

  • PROCEDURE Surgery
  • BIOLOGICAL denosumab

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2016-10
Est. Completion 2020-01-03
Phase Early Phase 1
NYU Langone Health

1,164 total trials

What the finished NCT02900469 record still lists

NCT02900469 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (17% lower).

The record links to 0 conditions, and to 2 interventions - of which Surgery is the first listed.

NCT02900469 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02900469 about?

NCT02900469 is a clinical study titled "Presurgical Trial of Denosumab in Breast Cancer". The purpose of this study is to determine whether one dose of denosumab can lead to changes in the tumor, which may decrease the ability of tumor to spread.

What is the current status of trial NCT02900469?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 44 participants. The study started on 2016-10. Estimated completion is 2020-01-03.

What interventions are being tested in trial NCT02900469?

The interventions under investigation include: Surgery (PROCEDURE), denosumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02900469?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02900469's enrollment target sits among peer trials

44 589th of 2000 higher than 1,402 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02900469, the US trial registry maintained by the National Library of Medicine. NCT02900469 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.